96 Tests PN: B113366

Components:

45x Ab-conjugated beads (S4P6 - human sEndoglin Ab-bead). PN: B113251A. One vial containing 100 µL of anti-human sEndoglin conjugated to AimPlex Bead S4P6.

25x Biotin-detection Ab (human sEndoglin Biotin-dAb). PN: B113251B. One vial containing 100 µL of biotinylated anti-human sEndoglin.

Lyophilized Standard Mix-Human Group 5 Panel B, 10-Plex. PN: HG50010. One vial containing lyophilized recombinant human sRANKL, sEndoglin, sVCAM-1, sE-selectin, sCD95L, sICAM-1, sCD25, sCD14, sTNFRI, and sCD40L.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.


Application: Optimal antibody pair and antigen standard for assaying human Endoglin/sCD105.  Can be multiplexed with other analytes in Human Group 5.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 5: Negligible

  • Sample volume: 15 µL/test

Description:

Endoglin (ENG) is a type I membrane glycoprotein located on cell surfaces and is part of the TGF beta receptor complex and is commonly referred to as CD105, END, FLJ41744, HHT1, ORW and ORW1. It has a crucial role in angiogenesis, therefore, making it an important protein for tumor growth, survival and metastasis of cancer cells to other locations in the body. Endoglin has been found to be an auxiliary receptor for the TGF-beta receptor complex.  It thus is involved in modulating a response to the binding of TGF-beta1, TGF-beta3, activin-A, BMP-2, and BMP-7. Beside TGF-beta signaling endoglin may have other functions. It has been postulated that endoglin is involved in the cytoskeletal organization affecting cell morphology and migration.  Endoglin has a role in the development of the cardiovascular system and in vascular remodeling. Its expression is regulated during heart development.  Experimental mice without the endoglin gene die due to cardiovascular abnormalities. In humans endoglin may be involved in the autosomal dominant disorder known as hereditary hemorrhagic telangiectasia type 1, the first human disease linked to the TGF beta receptor complex. This condition leads to frequent nose bleeds, telangiectases on skin and mucosa and may cause arteriovenous malformations in different organs including brain, lung, and liver.

References:

  1. Lopez-Novoa JM, Bernabeu C (January 2012). "ENG (endoglin)". Atlas of Genetics and Cytogenetics in Oncology and Haematology.

  2. Fernández-Ruiz E, St-Jacques S, Bellón T, Letarte M, Bernabéu C (1993). "Assignment of the human endoglin gene (END) to 9q34-->qter". Cytogenetics and Cell Genetics 64 (3-4): 204–7. doi:10.1159/000133576. PMID 8404038.

  3. Rodríguez-Peña A, Prieto M, Duwel A, Rivas JV, Eleno N, Pérez-Barriocanal F, Arévalo M, Smith JD, Vary CP, Bernabeu C, López-Novoa JM (2001). "Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction". Nephrology, Dialysis, Transplantation. 16 Suppl 1: 34–9. doi:10.1093/ndt/16.suppl_1.34. PMID 11369818.

  4. Michelle Letarte. "Structure and function of endoglin, a component of the TGF- beta receptor, etc." University of Toronto. Archived from the original on 2006-09-29. Retrieved